glp 1 intestinal issues Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms GLP-1 Agonists For Obesity In
Description
Pharmacological investigations have revealed that dopamine agonists can alleviate RLS symptoms, whereas dopamine antagonists may exacerbate them [3]

Dysregulation in liver metabolism, such as in nonalcoholic fatty liver disease (NAFLD), can increase cardiovascular risk

1,3,5 Intermediate-risk patients with values between 1.3 and 2.67 should undergo VCTE or ELF testing

References: [2] [3] [6] [7] [8] [11] [12] [13] [14] [16] [17] [18] [20] [21] [23] [24]

doi: 10.1016/j.jhep.2017.01.022
Most effects are temporary
